Tag: digital biomarkers

Background Traditional assessments of disease progression and intervention efficacy used in clinical trials are often limited. These assessments normally consist of clinical outcome assessments (COAs) and patient reported outcomes (PROs). COAs are physician-derived, often requiring patients to travel to a clinical site. They are typically subjective, episodic in nature, and provide limited insight into the […]